Can I Take Caffeine with Rezdiffra (Resmetirom)?

What Is Resmetirom (Rezdiffra) and Why Does the Liver Matter Here?

Resmetirom is a liver-directed, thyroid hormone receptor beta (THR-beta) selective agonist approved by the FDA on March 14, 2024, for adults with noncirrhotic MASH and liver fibrosis stages F2 or F3 [1]. Because it acts directly in hepatocytes, its interaction profile is inseparable from liver function, the same organ that metabolizes caffeine.

Mechanism of Action

Resmetirom binds selectively to THR-beta, which governs hepatic lipid oxidation, bile acid synthesis, and mitochondrial biogenesis [2]. Activation of THR-beta reduces intrahepatic triglyceride accumulation, lowers LDL-C by roughly 16-19%, and reduces hepatic fat fraction. In the MAESTRO-NASH trial (N=966), 26% of patients on 100 mg resmetirom achieved MASH resolution without fibrosis worsening at 52 weeks versus 10% on placebo (P<0.001) [3].

The Fibrotic Liver as a Pharmacokinetic Variable

Liver fibrosis itself alters drug metabolism. Patients with F2-F3 fibrosis may have reduced cytochrome P450 enzyme activity compared with healthy controls [4]. That means both resmetirom and caffeine are being processed in a liver that is already metabolically stressed, and any inhibitory effect on CYP enzymes becomes more clinically meaningful.

How Caffeine Is Metabolized, And Where Resmetirom Fits In

Caffeine clearance depends almost entirely on CYP1A2, which converts caffeine to paraxanthine (the primary active metabolite), theophylline, and theobromine [5]. CYP1A2 accounts for roughly 95% of this conversion in healthy adults [6].

Resmetirom's Effect on CYP1A2

The FDA pharmacology review for resmetirom (NDA 217674) identified resmetirom as a weak inhibitor of CYP1A2 in vitro [1]. In vitro inhibition does not automatically translate to clinically meaningful in vivo effects, but it creates a plausible mechanism for modestly prolonged caffeine half-life. Caffeine's normal half-life is 3-5 hours in healthy adults; conditions that inhibit CYP1A2 can extend it to 7-10 hours or longer [5].

What "Weak Inhibitor" Means Quantitatively

A weak CYP1A2 inhibitor is generally defined as one producing less than a 2-fold increase in the area under the curve (AUC) of a sensitive CYP1A2 substrate [7]. For caffeine, a 1.2-1.5-fold AUC increase is a reasonable working estimate based on in vitro data, this would translate to caffeine staying active in the body for perhaps 1-2 additional hours per dose. That is a modest effect for most patients, but in someone drinking four cups of coffee daily, accumulation over 24 hours becomes relevant.

CYP3A4 and Other Pathways

Resmetirom is itself a moderate CYP3A4 substrate [1]. Caffeine has minimal CYP3A4 involvement, so this pathway does not drive the caffeine interaction. The interaction runs primarily one direction: resmetirom weakly inhibiting the enzyme that clears caffeine, not the reverse.

Pharmacodynamic Interactions: Blood Pressure, Heart Rate, and Glucose

Beyond pharmacokinetics, caffeine and resmetirom share overlapping physiological territories that deserve separate assessment.

Cardiovascular Effects

Caffeine increases systolic blood pressure by 3-15 mmHg and heart rate by 3-7 beats per minute in acute ingestion studies, with the magnitude depending on habitual use and genetic CYP1A2 polymorphisms [8]. Patients prescribed resmetirom frequently carry the cardiovascular risk factors common in MASH: hypertension, type 2 diabetes, and obesity. A meta-analysis of 34 randomized trials (N=2,496) confirmed that caffeinated beverages raise systolic blood pressure acutely, with larger effects in non-habitual users [8].

Regular moderate caffeine intake (under 400 mg/day) does not appear to worsen long-term cardiovascular outcomes in the general population per an American Heart Association scientific statement [9]. However, patients in the MAESTRO-NASH trial had a mean BMI of 35.4 kg/m² and high rates of metabolic syndrome [3], populations where acute blood pressure excursions may carry more weight.

Glucose and Insulin Sensitivity

Acute caffeine ingestion impairs insulin-mediated glucose uptake, raising post-meal blood glucose by roughly 0.5-1.0 mmol/L in people with type 2 diabetes [10]. Resmetirom improved markers of insulin resistance in MAESTRO-NASH, reducing liver fat by a mean of 36% in the 100 mg group [3]. These effects are directionally opposed: resmetirom improves metabolic parameters while acute caffeine doses may blunt insulin sensitivity. Habitual caffeine use appears to reduce type 2 diabetes risk over the long term, though the acute post-meal glycemic effect remains an independent concern for patients on glucose-lowering therapies [10].

Hepatic Blood Flow Considerations

Caffeine is a vasoconstrictor. In patients with portal hypertension, a risk in patients approaching cirrhosis, caffeine may transiently increase portal pressure [11]. Patients prescribed resmetirom are noncirrhotic by indication, but F3 fibrosis puts some of them close to that threshold. Clinicians should factor this in when patients report high daily caffeine intake.

Epidemiological Signal: Does Coffee Help or Hurt MASH?

This is a nuance that most caffeine-drug interaction articles miss entirely. Epidemiological data consistently suggest that habitual coffee consumption is associated with lower MASH severity and slower fibrosis progression.

The Hepatoprotective Epidemiology

A systematic review of 16 observational studies found that coffee consumption of two or more cups daily was associated with a 39% lower odds of liver fibrosis in patients with nonalcoholic fatty liver disease (NAFLD/MASH) [12]. A separate analysis in Hepatology (N=782) found that coffee drinkers had significantly lower fibrosis scores than non-drinkers after adjusting for BMI, diabetes, and alcohol [13].

The proposed mechanisms include: cafestol and kahweol diterpenes in unfiltered coffee activating Nrf2 antioxidant pathways; caffeine itself inhibiting TGF-beta-driven hepatic stellate cell activation; and chlorogenic acids reducing de novo lipogenesis [12].

Reconciling Hepatoprotection with Pharmacokinetic Caution

These two lines of evidence point in different directions. The epidemiology suggests moderate coffee intake may support the same liver-health goals as resmetirom. The pharmacokinetics suggest that resmetirom could mildly slow caffeine clearance. Neither finding cancels the other. Moderate coffee consumption (1-2 cups, delivering roughly 100-200 mg caffeine per serving) is likely compatible with resmetirom therapy and may even be metabolically complementary, provided cardiovascular parameters are stable [9].

Dose-Timing, Practical Limits, and What to Monitor

No randomized clinical trial has directly studied the caffeine-resmetirom combination. The guidance below is constructed from resmetirom's FDA pharmacology review [1], caffeine's established CYP1A2 pharmacokinetics [5], and AASLD's 2023 MASH practice guidance [14].

Caffeine Dose Thresholds

The FDA's own caffeine guidance and peer-reviewed pharmacokinetic modeling suggest 400 mg/day as the general upper limit for healthy adults [15]. For patients on a weak CYP1A2 inhibitor with MASH, a conservative working ceiling of 200 mg per dose (roughly two standard 8 oz cups of brewed coffee) with no more than 400 mg total per day is a reasonable starting point. Energy drinks often deliver 150-300 mg per can and frequently contain additional stimulants (taurine, B vitamins, guarana) whose interactions with resmetirom are not characterized.

Timing Relative to Resmetirom Dosing

Resmetirom is taken once daily with food [1]. Its peak plasma concentration (Tmax) occurs at approximately 4 hours post-dose. Because the pharmacokinetic interaction runs from resmetirom inhibiting CYP1A2 (a hepatic enzyme that is active continuously), dose separation does not meaningfully reduce caffeine exposure the way it might for absorption-level interactions. Standard-timed morning coffee with the resmetirom dose is acceptable, but consuming large caffeine boluses (energy drinks, espresso shots stacked within an hour) should be avoided.

Monitoring Parameters

Patients starting resmetirom while consuming caffeine regularly should track these at each clinical visit:

• Resting heart rate and blood pressure at each visit. Target: heart rate below 80 bpm at rest, systolic blood pressure below 130 mmHg per ACC/AHA 2017 guidelines [16].
• Liver enzymes (ALT, AST) at 3-month intervals as recommended in the Rezdiffra prescribing information [1]. Caffeine at moderate doses does not raise transaminases in the absence of underlying liver disease, but any unexpected ALT rise above 3x the upper limit of normal warrants review of all hepatotoxic inputs.
• Fasting glucose and HbA1c for patients with concurrent type 2 diabetes or prediabetes, given caffeine's acute insulin-resistance effect [10].
• Sleep quality self-report. Because resmetirom's CYP1A2 inhibition may extend caffeine's half-life by 1-2 hours, patients who previously tolerated an afternoon coffee without sleep disruption may notice insomnia. Shifting caffeine intake to before noon is a practical first adjustment.

Special Populations Within the Resmetirom Label

Patients with Child-Pugh A cirrhosis are not candidates for resmetirom. Patients with F3 fibrosis approaching cirrhosis may have further reduced CYP1A2 activity independent of resmetirom [4]. Genetic CYP1A2 polymorphisms (slow metabolizers carry the *1F allele) compound this further. Patients who already report jitteriness, palpitations, or insomnia from caffeine before starting resmetirom are likely slow CYP1A2 metabolizers and should reduce intake proactively [6].

What the MAESTRO-NASH Trial Population Tells Us About This Question

The MAESTRO-NASH phase 3 trial enrolled 966 adults with biopsy-confirmed MASH and F1b-F3 fibrosis across 201 sites globally [3]. Key demographic data from the trial are directly relevant here.

Mean age was 56 years; 54% of participants were female; mean BMI was 35.4 kg/m²; 67% had type 2 diabetes; and 60% were on statins [3]. Cardiovascular risk was high across the cohort. The trial did not collect caffeine intake data, so no subgroup analysis of caffeine users exists. That absence is itself informative: the FDA accepted MAESTRO-NASH as adequate evidence of efficacy and safety without requiring caffeine restriction, suggesting that typical background caffeine use in a North American trial population was not considered a confound.

The AASLD 2023 practice guidance states: "Lifestyle modification including diet, exercise, and avoidance of alcohol remains the cornerstone of MASH management and should be reinforced at every clinical encounter" [14]. Coffee is not listed as a substance to avoid. Alcohol, on the other hand, is specifically flagged.

Drug Interaction Databases: What the Major References Say

The FDA-approved prescribing information for Rezdiffra (updated March 2024) lists resmetirom as a weak CYP1A2 inhibitor and advises monitoring for increased exposure of sensitive CYP1A2 substrates [1]. Caffeine is a benchmark CYP1A2 substrate used in drug interaction studies and is explicitly listed as such in FDA guidance for drug interaction studies [7].

The Natural Medicines database rates the caffeine-resmetirom interaction as "insufficient evidence" given the absence of a dedicated clinical interaction study, which does not mean no interaction exists, but that the magnitude has not been quantified in humans [17]. Mayo Clinic's drug interaction checker similarly flags the combination as warranting monitoring without recommending avoidance [18].

Theophylline, a caffeine metabolite and a standalone bronchodilator, is also a sensitive CYP1A2 substrate. Patients on theophylline who are prescribed resmetirom should have serum theophylline levels checked at baseline and 4 weeks after starting resmetirom, as the same CYP1A2 inhibition applies with potentially greater clinical consequence [5].

Clinical Decision Framework: Should You Continue Caffeine on Rezdiffra?

The answer depends on the patient's baseline cardiovascular status, habitual caffeine intake, and CYP1A2 phenotype.

Continue without change if: caffeine intake is under 200 mg/day (roughly one to two cups of brewed coffee), resting blood pressure is below 130/80 mmHg, heart rate is below 75 bpm, and the patient has no self-reported caffeine sensitivity symptoms [9].

Reduce and monitor if: daily intake is 200-400 mg, the patient has hypertension (even if controlled), or the patient reports new insomnia or palpitations after starting resmetirom.

Discuss stopping or strict limitation if: intake exceeds 400 mg/day, the patient has uncontrolled hypertension or paroxysmal arrhythmia, or LFTs are rising unexpectedly [1].

The hepatoprotective epidemiology means patients should not be reflexively told to quit coffee entirely. Two cups of filtered coffee per day delivering 100-200 mg caffeine sits in a range where the population-level liver benefit data are strongest [12].